Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a biotech filing can feel like decoding lab results in another language, especially when Sera Prognostics’ disclosures span clinical-trial endpoints, cash-burn tables and biomarker patents. If you have ever wondered how to track Sera Prognostics insider trading Form 4 transactions before pivotal data releases or needed to locate R&D spend buried deep in the notes, you know the challenge.
Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn a 300-page 10-K into a two-minute brief, flagging exactly where the company discusses pre-term birth biomarkers, partnership milestones and patent litigation risks. Real-time alerts surface every filing type the moment it hits EDGAR, including:
- Sera Prognostics quarterly earnings report 10-Q filing with segment growth and burn-rate trends
- Sera Prognostics annual report 10-K simplified for long-term obligations and IP strategy
- Sera Prognostics proxy statement executive compensation to benchmark leadership incentives
- Sera Prognostics 8-K material events explained for clinical-trial results or financing updates
- Sera Prognostics Form 4 insider transactions real-time so you never miss an executive stock move
Whether you’re analysing cash runway, comparing quarter-over-quarter biomarker adoption, or simply understanding Sera Prognostics SEC documents with AI, Stock Titan streamlines your workflow. Use the Sera Prognostics earnings report filing analysis to assess revenue from diagnostic sales, or dive into Sera Prognostics executive stock transactions Form 4 for sentiment signals. Complex biotech disclosures are now clear, timely and actionable—no scientific background required.
Sera Prognostics, Inc. filed a current report to share that findings from its Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (“PRIME”) study have been accepted for publication in a peer-reviewed journal. The company disclosed this information under a Regulation FD disclosure, indicating it was also announced in a press release dated November 24, 2025, furnished as an exhibit to the report.
Sera Prognostics (SERA) filed its Q3 2025 report, highlighting modest revenue and a continued focus on funding and operations. Revenue was $16 thousand for the quarter and $71 thousand year-to-date. The company reported a Q3 net loss of $7.8 million and a year-to-date net loss of $24.0 million, driven by operating expenses of $9.0 million in the quarter.
Liquidity strengthened earlier in the year from a February 2025 underwritten offering, delivering $53.6 million in net proceeds. As of September 30, 2025, cash, cash equivalents and marketable securities totaled $102.4 million, with total assets of $108.1 million and stockholders’ equity of $82.2 million. Operating cash used year-to-date was $19.5 million. Deferred revenue stood at $20.3 million, reflecting contractual arrangements to be recognized upon delivery of test results. The company amended and extended its headquarters lease in September 2025, with a noncurrent operating lease obligation of $2.4 million.
Sera Prognostics, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025. The company disclosed the results and business highlights via a press release furnished as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.
Sera Prognostics (SERA) reported an insider transaction by its Chief Executive Officer and Director. On 11/10/2025, the reporting person sold 11,594 shares of Class A common stock at a weighted average price of $2.62. The filing states the sale was executed to cover tax withholding obligations tied to the vesting of RSUs and was not a discretionary trade. The shares were sold via a block trade within a price range of $2.30–$3.04. Following the transaction, the insider beneficially owns 796,296 shares.
Sera Prognostics (SERA) insider transaction: the company’s Chief Data Officer reported a sell-to-cover trade tied to RSU vesting. On 11/10/2025, 7,073 shares of Class A common stock were sold to satisfy tax withholding, a non-discretionary transaction under the issuer’s “sell to cover” election.
The sale executed at a $2.62 weighted average price within a $2.30–$2.62 range. Following the transaction, the reporting person beneficially owns 168,596 shares, held directly.
Sera Prognostics (SERA): Form 4 insider transaction. The company’s General Counsel reported the sale of 7,059 shares of Class A common stock on 11/10/2025 at a weighted average price of $2.62. The filing states the shares were sold to satisfy tax withholding obligations tied to RSU vesting under a mandated “sell to cover,” indicating it was not a discretionary trade. Following the transaction, the insider directly beneficially owns 119,758 shares. The sale was executed as a block trade with prices ranging from $2.30 to $3.04.
Sera Prognostics (SERA) reported an insider transaction by its Chief Information Officer. On 11/10/2025, the officer sold 6,528 Class A common shares in a mandated “sell to cover” to satisfy tax withholding triggered by RSU vesting. The transaction is noted as non‑discretionary under the company’s election.
The shares were sold at a weighted average price of $2.62, with individual trades ranging from $2.30 to $3.04. Following the transaction, the reporting person beneficially owns 89,404 shares, held directly.
Sera Prognostics (SERA) insider transaction: the company’s Chief Scientific Officer reported a sale of 7,767 shares of Class A common stock on 11/10/2025 at a weighted average price of $2.62. The filing states the sale was made to cover tax withholding upon RSU vesting under a mandated “sell to cover” arrangement.
Following the transaction, the reporting person beneficially owned 151,726 shares, held directly. The block trade occurred across prices ranging from $2.30 to $3.04.
Sera Prognostics (SERA) disclosed an insider transaction by its Chief Financial Officer. On 11/10/2025, the officer sold 6,351 shares of Class A common stock at a weighted average price of $2.62 to cover tax withholding tied to RSU vesting, as required by the issuer’s sell-to-cover policy. The block trade occurred across multiple transactions priced between $2.30 and $3.04. After the sale, the officer beneficially owns 278,319 shares, held directly.
Sera Prognostics (SERA) filed a Form 4 reporting a routine sell-to-cover. On 11/05/2025, a director sold 221 shares of Class A common stock at a $3.04 weighted average price to satisfy tax withholding from vested RSUs. The filing notes the sale was mandated by the issuer’s “sell to cover” election and was not a discretionary trade by the insider. Following the transaction, the reporting person beneficially owns 58,032 shares, held directly. The shares were sold in multiple trades between $3.03 and $3.05.